Presentation of full TG01 phase I/II clinical trial results in resected pancreatic cancer, by Professor Daniel Palmer
Update on the TG mutRAS neoantigen vaccine development strategy
Review of recent ONCOS-102 interim data in melanoma and mesothelioma
OSLO, Norway, Oct. 12, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, will host a Capital Markets Day in Oslo on Monday 15 October 2018, from 08:30 – 10:15
The event will include a presentation by a world leading expert on pancreatic cancer, Professor Daniel Palmer, who is the Chair of Medical Oncology at the University of Liverpool and Clatterbridge Cancer Centre. Professor Palmer has been involved in a number of large international clinical studies in pancreatic cancer and was the Principal Investigator of Targovax's TG01 phase I/II trial in resected pancreatic cancer, in combination with adjuvant gemcitabine. Top-line survival data from the trial were released in May 2018 (see press release here) and at the upcoming event Professor Palmer will present the full study results.
Event venue: Hotel Continental, Oslo, Norway
Date: 15 October, 2018
Time: 08:30 – 10:15 CET
08:15 – 08:30: Registration and breakfast
08:30 – 08:40: Welcome remarks, Øystein Soug, CEO, Targovax
08:40 – 09:20: Resected pancreatic cancer: overview and TG01 full data, Prof. Daniel Palmer
09:20 – 09:40: Update on TG strategy, Øystein Soug, CEO, Targovax
09:40 – 09:50: ONCOS overview, Dr. Erik Digman Wiklund, CBO, Targovax
09:50 – 10:10: ONCOS-102 interim data in melanoma and mesothelioma, Dr. Magnus Jäderberg, CMO, Targovax
10:10 – 10:20: Financial and closing remarks, Dr. Torbjørn Furuseth, CFO, Targovax
A live webcast of the symposium will be available in the Events and Presentations section of the Targovax website.
To register for the event, please contact firstname.lastname@example.org.
For further information, please contact:
Renate Birkeli, Investor Relations
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
This information was brought to you by Cision http://news.cision.com